The Evolving Role of Patient Advocacy in Neuromuscular Research and Care: Paul Melmeyer, MPP

WATCH TIME: 3 minutes

Advances in neuromuscular disease research have expanded therapeutic possibilities across several conditions, including spinal muscular atrophy, Duchenne muscular dystrophy, and certain forms of myasthenia gravis. However, the development of new treatments does not necessarily translate into equitable access to specialized care, clinical trials, or approved therapies. For individuals living with rare and progressive neuromuscular disorders, challenges related to insurance coverage, affordability, disability services, and geographic access to multidisciplinary care can continue to complicate long-term disease management.

Patient advocacy organizations have become important participants in addressing these gaps, working alongside clinicians, researchers, policymakers, and regulatory agencies to support biomedical research and improve care delivery. Beyond raising awareness, these groups contribute to research priorities, encourage patient participation in clinical development, and advocate for policies that support treatment access and disability rights. Collaborative efforts across disease-specific organizations may also provide opportunities to address challenges shared by multiple neuromuscular communities.

“These organizations are imperative to fostering an environment in which biomedical research is being funded and that it's happening, and it's actually resulting in discoveries for neuromuscular disease patients. Also, these organizations are critical [to] ensuring that our care ecosystem, our care infrastructure ... [is] collaborating to ensure our community is receiving the very best care that they possibly can.”

Ahead of the 2027 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, NeurologyLive® spoke with Paul Melmeyer, MPP, executive vice president of public policy and advocacy at the MDA. Melmeyer has been closely involved in the growth of the Neuromuscular Advocacy Collaborative (NMAC), a coalition that brings together organizations representing individuals affected by neuromuscular diseases. The collaborative traditionally convenes during the annual MDA conference but has increasingly expanded its activities throughout the year.

In the conversation, Melmeyer discussed how NMAC's structure and priorities have evolved, including the transition toward more frequent collaboration and coordinated advocacy campaigns. He also examined the broader contributions of patient organizations to research funding, clinical trial development, regulatory policy, treatment access, and the delivery of comprehensive neuromuscular care.